# Emily Nieves

> Emily Nieves is the co-founder and CEO of Delineate, a Cambridge, Massachusetts startup building AI agents that read the scientific literature the way a pharmacologist does - pulling numbers out of buried plots and patents to speed up drug development. A University of Georgia biological engineer turned MIT PhD researcher, she worked on computational modeling at Pfizer and AstraZeneca before deciding the bottleneck wasn't the models but the months it took to feed them. Delineate, part of Y Combinator's Winter 2025 batch, now works with top-10 pharma companies to turn months of systematic review into weeks.

- **Role:** Co-Founder & CEO at Delineate
- **Organizations:** Delineate, Massachusetts Institute of Technology (MIT), Pfizer, AstraZeneca, University of Georgia
- **Education:** B.S. in Biological Engineering (research in the Hallow cardiorenal lab), University of Georgia, PhD candidate, Biological Engineering, Massachusetts Institute of Technology (MIT)
- **Known for:** Co-founded and leads Delineate, an AI company accepted into Y Combinator's Winter 2025 batch, Built a product used by two top-10 pharmaceutical companies for large-scale systematic review, Delineate reports processing 15x more studies than the industry standard and cutting some study timelines from months to weeks

## Career timeline

- **earlier** — Undergraduate biological engineering research at the University of Georgia, working in the Hallow cardiorenal laboratory
- **earlier** — Computational researcher at Pfizer and AstraZeneca, building models across cardiorenal systems, metabolism, and cell therapies
- **ongoing** — PhD candidate in Biological Engineering at MIT, working at the intersection of AI and pharmacology
- **2024** — Co-founded Delineate with Jawad Iqbal; became CEO
- **2025** — Delineate selected for Y Combinator's Winter 2025 batch; raised seed funding
- **2024** — Presented 'Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology' at the American Conference of Pharmacometrics (ACoP)
- **2025** — Speaker and panelist at ISOP ACoP 2025 on GenAI in modern pharmacometric workflows

## Achievements

- Co-founded and leads Delineate, an AI company accepted into Y Combinator's Winter 2025 batch
- Built a product used by two top-10 pharmaceutical companies for large-scale systematic review
- Delineate reports processing 15x more studies than the industry standard and cutting some study timelines from months to weeks
- Conference speaker and panelist at ACoP / ISOP on GenAI in pharmacometrics
- Pursuing a PhD in Biological Engineering at MIT while running a venture-backed startup

## Latest updates

- **2025-10** — Speaker and panelist at ISOP ACoP 2025 on 'Envisioning the Role of GenAI in Modern Pharmacometric Workflows.'
- **2025-04** — Delineate closed seed funding; participated in Y Combinator's Winter 2025 batch.

## Links

- Website: https://delineate.pro
- LinkedIn: http://www.linkedin.com/in/emily-nieves-a67b90144

---

Profile page: https://yespress.io/emily-nieves
Published by YesPress — https://yespress.io
Last updated: 2026-06-24